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Discovered in the last decade, Heliobacter pylori is now known
to play a role in the onset of chronic gastritis and peptic ulcer and
also to be strongly associated with gastric cancer and Mucosa-
Associated Lymphoid Tissue (MALT) lymphoma [1,2]. These
findings have revolutionized the therapeutical approach to gas-
tric pathology. Moreover, the wide spread of dyspeptic symp-
toms has contributed to the development of a variety of
noninvasive diagnostic assays, such as the urea breath test, sero-
logic and whole blood tests, most of which are available to the
primary care physicians for the rapid diagnosis of H. pylori
infection. As a consequence, antibiotic eradication therapy has
been widely applied, often without endoscopic examination
which is essential for the identification of the cause of the
gastric pathophysiological disturbances. At present, the most
commonly used treatment is the triple therapy: a proton pump
inhibitor and two antibiotics (metronidazole plus clar-
ithromycin, or amoxycillin plus clarithromycin, or metron-
idazole plus amoxycillin) [3]. Because of the abuse of this
therapeutic scheme, a consistent increase in metronidazole and
clarithromycin resistance among H. pylori strains has been moni-
tored [4,5]. Recently the first case of an amoxycillin-resistant
H. pylori strain has also been reported [6]. The appearance of
resistant strains is one of the major causes of treatment failure
[7]. Thus, monitoring the prevalence of resistant strains and
establishing the local susceptibility level to the commonly used
drugs is at least as important as the development of new anti-
microbial agents. For this reason and because of the high inci-
dence of gastric cancer in our region [8,9] (the southern part of
Switzerland together with the northern part of Italy) we col-
lected 142 H. pylori strains from different patients living in the
Cantone Ticino (southern part of Switzerland) in 1996 and
1997. These strains were tested for susceptibility to metron-
idazole, clarithromycin and amoxycillin.
Minimum inhibitory concentrations (MICs) of 142 H. pylori
strains were determined using the E-test method (AB Biodisk,
Solna, Sweden) according to the manufacturer’s instructions.
The MIC breakpoint values for H. pylori resistance were chosen
according to the available data published in the literature:
8 mg/L for both metronidazole and clarithromycin, and 2 mg/L
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for amoxycillin [7,10,11]. Strains with MICs for metronidazole
and clarithromycin between 2 and 6 mg/L were defined as
intermediate. For each patient, gastroenterologists were asked
to complete a questionnaire on the gastroduodenal disease, age,
sex, family gastric pathology history and previous treatment
against H. pylori infections. The endoscopic diagnosis of the
disease was confirmed by pathological examination of the gas-
tric biopsy performed at the Istituto Cantonale di Patologia
(Locarno, Switzerland). For the patients harbouring resistant
strains of H. pylori, an attempt to determine the previous use
of the corresponding drug was made: the patient’s general
practitioner was asked to give details of previous prescriptions
of either metronidazole, clarithromycin or amoxycillin. The
selected patient population included 70 female and 72 male
subjects with a mean age of 50 years (range 13–86 years).
Ninety-five patients (67%) presented chronic gastritis, 28 duo-
denal ulcer (19.7%), nine gastric ulcer (6.3%), two (1.4%) gastric
MALT lymphoma, four (2.8%) dyspepsia and four (2.8%) other
gastric diseases. The Ethical Committee of the Cantone Ticino
approved this work and informed consent was obtained from
all patients.
Tables 1 and 2 summarize the results obtained with sus-
ceptibility testing. Of the 142 isolates, none were found to
be resistant to amoxycillin (MIC  2 mg/L), 17 (12%) were
resistant to clarithromycin (MIC  8 mg/L) and 41 (29%) were
resistant to metronidazole (MIC  8 mg/L). The MIC dis-
tributions for the three antibiotics are shown in Figure 1. These
results are in agreement with the prevalence of resistant H.
pylori strains reported for other European countries [5,12]. In
Germany, the prevalence of metronidazole resistance is 32%
[13], in Italy 24.9% [14], in the UK 37% [15], in Belgium 27%
[5], in Ireland 33.8% [11] and in The Netherlands 17% [7]. The
prevalence of clarithromycin resistance is 3.3% in Germany,
4.2% in the UK [15], 10% in France [16,17], 4.5% in Ireland
[18,19] and 1% in The Netherlands [7]. No amoxycillin-resist-
ant H. pylori has ever been found, apart from the case report of
van Zwet et al. [6]. A detailed analysis of the data shows that
the majority of the metronidazole-resistant strains were isolated
from female patients (63.4%, P = 0.032). At least 36.6% of the
Concise communications 39
Table 1 Prevalence of H. pylori
strains resistant to
metronidazole, clarithromycin
and amoxycillin
Patients MTZR* CLAR* AMOR* MTZR and CLAR
Males (n = 72) 15 (10.6%) 8 (5.65%) 0 6 (4.2%)
Females (n = 70) 26 (18.3%) 9 (6.35%) 0 5 (3.5%
Total (n = 142) 41 (28.9%) 17 (12.0%) 0 11 (7.7%)
*MTZR, CLAR, AMOR, resistant to metronidazole, clarithromycin, amoxycillin, respectively.
Values in brackets are percentage of the whole population.
Figure 1 Distribution of the MICs of metronidazole, clarithomycin
and amoxycillin for 142 isolates of H. pylori. Black and grey columns
represent resistant and intermediate strains, respectively.
patients harbouring strains that were resistant to metronidazole
had already been treated with this drug prior to endoscopic
examination. Clarithromycin resistance was equally distributed
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among male and female patients, but was significantly more
prevalent (82.4%) in strains originating from patients who had
been previously treated with this antibiotic. It was found that
7.7% of the tested strains were resistant to both clarithromycin
and metronidazole. Patients with ulcer did not present a higher
prevalence of resistant strains than patients with nonulcer
diseases.
The emergence of resistant strains of H. pylori is a matter of
concern in the management of gastric pathologies, because, in
addition to poor patient compliance, resistance is the major
cause of treatment failure [7]. The role of drug consumption in
drug resistance selection is confirmed by the fact that a sig-
nificantly higher prevalence of metronidazole-resistant strains
were isolated in female patients (63.4% in this study). Metron-
idazole is widely used to treat gynaecological infections in
particular. In addition, in our survey, the majority (82.4%) of
the clarithromycin-resistant isolates were found in patients
who had previously undergone clarithromycin-based treat-
ment.
From a medical microbiological point of view, the emerg-
ence and spread of resistant strains has become of major import-
ance. This problem is further complicated by the fact that H.
pylori is naturally competent [20], and therefore the acquisition
of resistance genes from other Helicobacter strains or from other
micro-organisms is increased. General practitioners should pre-
scribe antibiotics only when H. pylori has been established as
the real cause of the clinical manifestation and of the gastro-
pathological disorder. Susceptibility testing should be per-
formed as often as possible in order to prevent treatment failure
or the emergence of multiple-resistant H. pylori strains which
are difficult or impossible to eradicate.
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Table 2 Minimal inhibitory
concentrations (MIC) of
metronidazole, clarithromycin
and amoxycillin for
clinical isolates of H. pylori
MIC (mg/L)
Antibiotic MIC50 MIC90 Geometric mean Range
Metronidazole 1 32 2.145 0.016–32
Clarithromycin 0.032 12 0.090 0.016–256
Amoxycillin 0.016 0.032 0.022 0.016–0.094
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